• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Remote consultation video
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Laboratory Practice
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Current treatments

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print].

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients.
Blanes M et al. Leuk Lymphoma. 2014 May 14:1-17. [Epub ahead of print].

Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ et al. Eur J Haematol. 2014 May 9. doi: 10.1111/ejh.12377. [Epub ahead of print].

Complete response after autologous stem cell transplant in multiple myeloma.
Kumar L et al. Cancer Med. 2014 Apr 29. doi: 10.1002/cam4.257. [Epub ahead of print].

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma.
Campbell P et al. Blood Cancer J. 2014 May 9;4:e213. doi: 10.1038/bcj.2014.33.

Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective-A report by Polish Myeloma Study Group.
Walter-Croneck A et al. Leuk Res. 2014 May 4. pii: S0145-2126(14)00122-2. doi: 10.1016/j.leukres.2014.04.011. [Epub ahead of print].

  • Guidelines
  • Patient Support and Information
  • Medical animations
  • Remote consultation video
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG